Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
2013 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Frequency of HER-2 Positivity in Rectal Cancer and Prognosis
Conradi, L.-C. ; Styczen, H.; Sprenger, T. ; Wolff, H. A. ; Roedel, C.; Nietert, M. M. & Homayounfar, K. et al. (2013)
American Journal of Surgical Pathology, 37(4) pp. 522-531. DOI: https://doi.org/10.1097/PAS.0b013e318272ff4d
Documents & Media
Details
- Authors
- Conradi, Lena-Christin ; Styczen, Hanna; Sprenger, Thilo ; Wolff, Hendrik Andreas ; Roedel, Claus; Nietert, Manuel M. ; Homayounfar, Kia ; Gaedcke, Jochen ; Kitz, Julia ; Talaulicar, Recca; Becker, Heinz; Ghadimi, Michael B. ; Middel, Peter; Beißbarth, Tim ; Rüschoff, Josef R. ; Liersch, Torsten
- Abstract
- In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3(+) or silver in situ hybridization ratios of >= 2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P = 0.1) and a benefit in CSS (P = 0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P < 0.00001) and R status (P = 0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials.
- Issue Date
- 2013
- Status
- published
- Publisher
- Lippincott Williams & Wilkins
- Journal
- American Journal of Surgical Pathology
- ISSN
- 1532-0979; 0147-5185
- Sponsor
- Deutsche Forschungsgemeinschaft [KFO 179-2]